Cereno Scientific receives granted patent for CS1 expanding protection in Australia
Cereno Scientific (XSAT: CRNO B) today announced that intellectual property rights (IPR) for drug candidate CS1’s second patent family has been granted in Australia. This is a result of Cereno’s continuous work in securing IPR for its assets to strengthen the commercial positioning. A Phase II study evaluating CS1 for the treatment of pulmonary arterial hypertension (PAH) is planned to start in September 2021.
“We are pleased to strengthen the protection around our drug candidate CS1. The addition of also covering Australia for CS1’s second patent family, together with previously granted key markets Japan, Russia and the US is part of our ongoing strategic IPR work to secure an advantageous position ahead of future developments,” says Sten R. Sörensen, CEO at Cereno Scientific.
The patent granted in the Australian market is titled “Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation”, with patent number 2015329795 B2. This patent for Australia will be valid through 2035, with the possibility of a patent extension of additional five years maximum.
The Phase II study intends to demonstrate drug candidate CS1’s safety, tolerability, pharmacokinetics and exploratory efficacy in patients with the rare disease PAH. The study is planned to be initiated in September 2021.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study for CS1 in PAH is expected to be initiated in September 2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.